● Recruiting

TAD After Chemotherapy in Locally Advanced Breast Cancer

Condition: Sentinel Lymph Node · Breast Cancer · Locally Advanced · Sponsor: Hospital Universitari de Bellvitge

PhaseN/A

Planned participants162

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

This description comes directly from the study's public registry record.

Talk to the study team

Amparo García-Tejedor, MDPhD · 0034-932607702 · agarciat@bellvitgehospital.cat

Always discuss trial participation with your own doctor first.

Locations (2)

Hospital de Bellvitge	L'Hospitalet de Llobregat, Barcelona, Spain	Recruiting
Hospital Clínico y Provincial de Barcelona	Barcelona, Spain	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05763641